Teva, AbbVie To Face Trial Over Niaspan Pay-For-Delay Claims

By Lauren Berg · October 31, 2026, 12:04 AM EDT

Long-running multidistrict litigation over AbbVie and Teva Pharmaceuticals' agreement to delay generic forms of cholesterol drug Niaspan is headed toward trial, after a Pennsylvania federal judge Friday found a genuine dispute...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

IN RE: NIASPAN ANTITRUST LITIGATION

Case Number

2:13-md-02460

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

September 17, 2013